ranolazine ER / Generic mfg. - LARVOL DELTA

Cardioprotective effects of the ranolazine in myocardial infarction mediated by stimulation of the endogenous mediators involved in ischemic preconditioning. (PubMed, Acta Cir Bras) - "ranolazine can be a pharmacological alternative to surgical ischemic preconditioning utilized prior to interventional procedures like coronary artery bypass graft surgery and heart transplantation, offering improved patient compliance."

Journal • Cardiovascular • Myocardial Infarction • Reperfusion Injury • Transplantation • MB

Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma. (PubMed, Cell Death Dis) - "The AR antagonist enzalutamide sensitises AR expressing melanoma cells to RSL3 and erastin independent of phenotype state, but in FAOhigh BRAFi relapsed tumours AR up-regulation correlates with the undifferentiated/neural-crest like (UD/NC) state, and enzalutamide synergises with ranolazine in ferroptosis-induction in UD/NC cells. Thus, therapeutically combining ranolazine with the AR inhibitor enzalutamide to induce ferroptosis can circumvent dedifferentiation related BRAFi resistance and could increase therapeutic activity and long-term efficacy."

Journal • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor • AR • ATXN1L

TREATMENT PATTERNS AND OUTCOMES IN OLDER PATIENTS WITH CORONARY MICROVASCULAR DYSFUNCTION: US MEDICARE ANALYSIS (ACC 2026) - "Anti-anginal therapy was underutilized post-diagnosis: 4.6% (n=183) were on beta-blockers, 2.1% (n=86) on calcium channel blockers, 1.3% (n=52) on nitrates, and 0.8% (n=32) on ranolazine. This US real world study of older patients reveals high MACE rates but low use of invasive coronary physiology testing and anti-anginal therapy after CMD diagnosis, highlighting opportunities to optimize care in this at-risk population."

Clinical • Medicare • Reimbursement • US reimbursement • Cardiovascular • Dyslipidemia • Genetic Disorders • Myocardial Infarction • Obesity • Peripheral Arterial Disease

CABOZANTINIB-INDUCED VASCULAR TOXICITY RESULTING IN DIFFUSE CORONARY THROMBOSIS (ACC 2026) - "Over the next month, he had multiple readmissions for angina with recurrent troponin elevation despite nitrates, ranolazine, and anticoagulation... Cabozantinib can precipitate diffuse coronary thrombosis and recurrent ACS. Careful distinction from dissection is critical, as management strategies differ. In select patients, combination therapy with DAPT and rivaroxaban may reduce recurrence when standard therapy is insufficient."

Cardiovascular • Diabetes • Dyslipidemia • Genito-urinary Cancer • Hematological Disorders • Hypertension • Metabolic Disorders • Pulmonary Embolism • Renal Cell Carcinoma • Respiratory Diseases • Solid Tumor • Thrombosis

USE OF RANOLAZINE FOR HYPERTROPHIC CARDIOMYOPATHY: A SYSTEMATIC REVIEW (ACC 2026) - "Ranolazine can be considered a safe and effective adjunct in HCM, offering symptom relief and arrhythmia suppression. While it may not significantly improve exercise tolerance or diastolic function, its favorable tolerability profile makes it a viable option for patients with refractory symptoms. Further large-scale trials are needed to determine its long-term benefits in disease modification and arrhythmia prevention."

Review • Cardiomyopathy • Cardiovascular • Genetic Disorders • Hypertrophic Cardiomyopathy • Pulmonary Disease

SYSTEMATIC REVIEW OF PHARMACOLOGIC THERAPIES FOR NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (ACC 2026) - "Cardiac myosin inhibitors (CMIs) lowered pro-brain natriuretic peptide and troponin, improved diastolic indices, and induced modest left ventricular remodeling; aficamten improved functional status in contrast to mavacamten...Renin-angiotensin-aldosterone system (RAAS) agents were largely neutral, but valsartan improved a composite remodeling score in early nHCM. Metabolic modulators were inconsistent - perhexiline and ninerafaxstat showed some benefits, while ranolazine and trimetazidine did not. CMIs show the most consistent efficacy, followed by SGLT2is and cibenzoline; RAAS agents and metabolic modulators provide variable or limited benefit. Further trials are needed to clarify the role of SGLT2is and CMIs in nHCM."

Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

RANOLAZINE-INDUCED THROMBOCYTOPENIA AND NEUTROPENIA: A CASE REPORT (ACC 2026) - "Blood dyscrasias are a rare consequence of ranolazine treatment and should be considered if they develop after its initiation. Ranolazine's adverse effects were likely potentiated by diltiazem, a moderate CYP3A4 inhibitor, therefore these agents should be used cautiously in combination. Although this is a rare occurrence with no other reports, clinicians should maintain a high index of suspicion for hematologic abnormalities in patients receiving ranolazine, particularly when combined with CYP3A4 inhibitors."

Case report • Clinical • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Hematological Disorders • Hypotension • Neutropenia • Thrombocytopenia

Personalized management of angina and heart failure in clinical practice in the Middle East: a narrative review. (PubMed, J Comp Eff Res) - "Clinicians should consider adding newer antianginal agents (long-acting nitrates, ranolazine, trimetazidine, ivabradine) to beta-blockers + calcium-channel blockers based on patient risk factors. In patients with HF with reduced ejection fraction in sinus rhythm and elevated heart rate, ivabradine should be added to maximum tolerated doses of beta-blockers. Adding ivabradine to first-line therapy improves heart rate control and QoL, and reduces HF-related hospitalization and mortality."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction

Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study (clinicaltrials.gov) - P2/3 | N=100 | Recruiting | Sponsor: Federico II University | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Myocardial Infarction

Frequently Underappreciated Considerations in Anti-arrhythmic Drug Therapy. (PubMed, J Innov Card Rhythm Manag) - "These factors are discussed in this paper as a means of improving AAD use by clinicians and tolerance by patients. Notably, it is only these issues that are the focus of this paper, which is not meant as a review of the pharmacologic profile of each of our AADs."

Journal • Review • Cardiovascular

What Is in the Myopathy Literature? (PubMed, J Clin Neuromuscul Dis) - "This update begins with a discussion of treatable lipid storage myopathies associated with the use of sertraline and ranolazine. Pompe disease follows with a focus on enzyme replacement therapy data. A short section on congenital myopathies precedes a review of reports on myotonic dystrophies and nondystrophic myotonias."

Journal • Immunology • Monoclonal Gammopathy • Muscular Dystrophy • Myositis • Myotonic Dystrophy • Pompe Disease

Inhibition of late sodium current (INa) to prevent coronary MICROvascular dysfunction in patients presenting with ST-Elevation myocardial infarction and multivessel disease: A multicenter, randomized, controlled and open label study (INaMICRON study) (clinicaltrialsregister.eu) - P1/2 | N=100 | Not yet recruiting | Sponsor: Universita' Degli Studi Di Napoli Federico II

New P1/2 trial • Cardiovascular • Myocardial Infarction

Comparative Study of the Efficacy of Ranolazine as Add-On Therapy With Metformin Versus Metformin Monotherapy on Glycaemic Control in Patients of Type 2 Diabetes Mellitus. (PubMed, Cureus) - "Ranolazine, when added to metformin, provides incremental and statistically significant improvements in glycaemic control, supporting its potential role as an adjunct therapy in T2DM. Larger, longer-term studies are warranted to confirm durability and cardiovascular benefits."

Journal • Monotherapy • Cardiovascular • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of GS-967, GS-6615 and ranolazine on the responses of the rabbit aorta to adrenergic nerve stimulation. (PubMed, Front Physiol) - "Electrical Field Stimulation (EFS) (2, 4 and 8 Hz) induced frequency-dependent contractions that were abolished by tetrodotoxin, prazosin, or guanethidine (10-6 M)...Concentration-response curves to GS-967, GS-6615 or RAN were constructed in rings precontracted with noradrenaline, endothelin-1 or KCl with or without specific inhibitors (L-NAME, nimesulide, SC-560, verapamil, nifedipine, apamin or charybdotoxin)...Taken together, our results indicate that GS-967, GS-6615 and RAN decrease vasoconstrictor responses due to both neural and noradrenaline-induced adrenergic stimuli. We can suggest that the use of GS-967, GS-6615 and Ranolazine may be interesting in clinical procedures involving hyperstimulation of the adrenergic nervous system."

Journal • Preclinical • EDN1

Ranolazine attenuates diabetic cardiomyopathy in rats by suppressing AGE-RAGE axis and oxidative stress. (PubMed, BMC Res Notes) - No abstract available

Journal • Preclinical • Cardiomyopathy • Cardiovascular • Diabetes • Metabolic Disorders

Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study (clinicaltrials.gov) - P2/3 | N=100 | Not yet recruiting | Sponsor: Federico II University

New P2/3 trial • Cardiovascular • Myocardial Infarction

Mutation-specific roles of sustained sodium current (INa) in guiding precision medicine for long QT syndrome type 3. (PubMed, PNAS Nexus) - "Electrophysiological properties were analyzed using patch-clamp techniques, and pharmacological responses to flecainide, mexiletine, and ranolazine were evaluated. This study highlights the role of sustained INa in LQTS3 severity and underscores the importance of mutation-specific treatments. By tailoring treatments to the electrophysiological characteristics of each mutation, precision medicine offers a promising approach to improving patient outcomes in LQTS3."

Journal • Cardiovascular

Association between ranolazine therapy and cognitive decline in elderly patients with ischemic heart disease. (PubMed, Front Pharmacol) - "The use of Ranolazine is associated with a significant odds reduction in CoI in elderly patients with IHD and multiple comorbidities. The neuroprotective effect of Ranolazine may be attributed to the improvement of anginal symptoms and consequent optimization of functional status and quality of life, advocating for a comprehensive therapeutic strategy in geriatric patient management."

Journal • Acute Coronary Syndrome • Alzheimer's Disease • Cardiovascular • Cognitive Disorders • Coronary Artery Disease • Diabetes • Geriatric Disorders • Heart Failure • Metabolic Disorders • Sarcopenia • Type 2 Diabetes Mellitus

Quinidine-Induced Microvolt Electrocardiographic Alternans. (PubMed, Annu Int Conf IEEE Eng Med Biol Soc) - "The study population belongs to the "ECG Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects" database. Furthermore, ECGA magnitude seemed to reveal transient changes better than amplitude, resulting in more post-dose time points, especially in the range 3.5-7 hours after quinidine administration, at which ECGA was statistically different than at the pre-dose time point. Thus, ECGA appears to disclose the higher risk of arrhythmia associated with quinidine.Clinical Relevance- The present study provides a contribution to guide therapy involving quinidine through the analysis of its proarrhythmic risk by electrocardiographic alternans."

Journal • Cardiovascular

The Seattle Angina Questionnaire and Quality of Life in Chronic Coronary Syndrome: Opportunities for Implementation in Bulgarian Clinical Practice-A Narrative Review. (PubMed, Medicina (Kaunas)) - "Mechanism-tailored therapy maps to endotypes (e.g., VSA → CCB ± nitrates; MVA → beta-blocker/ACEi/statin ± ranolazine; obstructive CADGDMT ± PCI/CABG)... A clinically structured framework clarifies how the SAQ adds value beyond description-by informing triage, treatment selection, and follow-up across CCS phenotypes. This approach provides educational guidance and a practical blueprint for pilot implementation in Bulgaria."

HEOR • Journal • Review • Cardiovascular

Bioequivalence and Safety Study of Ranolazine Extended-Release Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: A Randomized, Open-Label, Single-Dose, Cross-Over, Comparative Pharmacokinetic Study. (PubMed, Clin Ther) - P1 | "The test formulation, ranolazine extended-release tablets, demonstrated a similar safety profile to the reference formulation, Ranexa, and was shown to be bioequivalent in healthy Chinese subjects in both fasting and fed conditions."

Journal • PK/PD data

The real-world safety profile of ranolazine: pharmacovigilance analysis of the FAERS database. (PubMed, Front Pharmacol) - "The results present vital safety information for physicians prescribing ranolazine. Notably, this study only identifies safety signals and does not establish causal relationships between ranolazine and the observed adverse events."

Adverse events • Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular • CNS Disorders • Constipation • Coronary Artery Disease • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hypertension • Hypotension • Movement Disorders • Myocardial Infarction • Otorhinolaryngology • Pain • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Xerostomia

A QSPR study of coronary artery disease drugs using eccentricity-based indices. (PubMed, Sci Rep) - "This study advances QSPR modeling by using eccentricity-based graphical invariants, specifically designed to enhance the predictive accuracy for physicochemical properties of drugs used to treat coronary artery disease, including atorvastatin, simvastatin, rosuvastatin, aspirin, clopidogrel, metoprolol, atenolol, enalapril, lisinopril, amlodipine, diltiazem, nitroglycerin, isosorbide dinitrate, ranolazine, gemfibrozil, and fenofibrate. The experimental values were compared with forecasted data, revealing a strong correlation between them. This demonstrates the reliability of our regression models in assessing these vital physicochemical parameters."

Journal • Cardiovascular • Coronary Artery Disease

Development trend analysis of ranolazine, based on bibliometrics. (PubMed, Medicine (Baltimore)) - "Currently, the research focus in this field primarily centers on 3 key aspects: the anti-angina effect, the electrophysiological characteristics and anti-arrhythmic effect and other effects of ranolazine. The future research direction in this field is likely to focus on the neuroprotective effect of ranolazine, its antitumor metastasis effect and its effect on atrial fibrillation and diabetes patients on the basis of maintaining the current research focus."

Journal • Atrial Fibrillation • Cardiovascular • Diabetes • Metabolic Disorders • Oncology

Cost-Effectiveness Model of Ranolazine for Treating Chronic Stable Angina Patients From Kingdom of Saudi Arabia Perspective (ISPOR-EU 2025) - "This insight, along with the importance of stratifying outcomes by angina severity and including revascularization impacts, guided the development of a 1-year decision tree model which compared ranolazine+sublingual nitro-glycerine (SNG) against placebo+SNG and trimetazidine+SNG. Trimetazidine was selected as the comparator due to its lower cost, high prevalence (approximately 95%) in Saudi Arabian second-line treatments, and superior safety profile compared to Ivabradine... Ranolazine is a cost-effective treatment compared to placebo and trimetazidine from KSA payor perspective. These findings are vital for optimizing healthcare resource allocation and ensuring patient access amidst rising costs."

Clinical • Cost effectiveness • HEOR • Cardiovascular